Clinical and pharmacological experience with etanercept

Bibliography

• HARRIS ED JR: Rheumatoid arthritis. Pathophysiologyand implications for therapy. New Engl. J. Med. (1990) 332:1277–1289.
   Google Scholar
• KORNER H, SEDGWICK JR: Tumour necrosis factor andlymphotoxin: molecular aspects and role in tissue-specific autoimmunity. Immunol. Cell Biol. (1996) 74:463–72.
   Google Scholar
• MORELAND LW: Inhibitors of tumor necrosis factor forrheumatoid arthritis. J. Rheumatol. (1999) 57 (Suppl. 26):7–15.
   Google Scholar
• MOHLER KM, TORRANCE DS, SMITH CA et al: Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antago-nists. J. Immunol. (1993) 151:1548–61.
   PubMed Web of Science ®Google Scholar
• POBER JS, GIMBRONE MA JR, LAPIERRE LA, MENDRICK DL, FIERS W, ROTHLEIN R et al.: Overlapping patterns of activation of human endothelial cells by interleukin 1, tumor necrosis factor, and immune interferon. J. Immunol. (1986) 137:1893–6.
   PubMed Web of Science ®Google Scholar
• LEIBOVICH SJ, POVERINI PJ, SHEPARD HM, WISEMAN DM, SHIVELY V, NUSEIR N: Macrophage-induced angiogenesis is mediated by tumor necrosis factor-a. Nature (1987) 329:630–2.
   PubMed Web of Science ®Google Scholar
• STREITER RM, KUNKEL SL, SHOWELL HJ, REMICK DG, PHAN SH, WARD PA et al:Endothelial cell gene expres-sion of a neutrophil chemotactic factor by TNF-a, LPS, and 11-113. Science (1989) 243: 1467–9.
   PubMed Web of Science ®Google Scholar
• LUPIA E, MONTRUCCHIO G, BATTAGLIA E, MODENA V, CAMUSSI G: Role of tumor necrosis factor-a and platelet-activating factor in neoangiogenesis induced by synovial fluids of patients with rheumatoid arthritis. Eur. j Immunol. (1996) 26:1690–94.
   PubMed Web of Science ®Google Scholar
• PALEOLOG EM, YOUNG S, STARK AC, MCCLOSKEY RV,FLEDMAN M, MAINI RN: Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor a and interleukin-1 in rheumatoid arthritis. Arthritis Rheum. (1998) 41:1258–65.
   PubMed Web of Science ®Google Scholar
• BERTOLINI DR, NEDWIN GE, BRINGHAM TS, SMITH DD, MUNDY GR: Stimulation of bone resorption and inhibi-tion of bone formation in vitro by human tumour necrosis factors. Nature (1986) 319:516–18.
   PubMed Web of Science ®Google Scholar
• SAKLATVALA J: Tumor necrosis factor a stimulates resorption and inhibits synthesis of proteoglycan in cartilage [Letter]. Nature (1986) 322:547–49.
   PubMed Web of Science ®Google Scholar
• VASSALLI P: The pathophysiology of tumor necrosis factors. Ann. Rev. Immunol. (1992) 10:411–52.
   PubMed Web of Science ®Google Scholar
• DINNARELLO CA, CANNON JG, WOLFF SM, BERNHEIM HA, BEUTLER B, CERAMI A et al. Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1. J. Exp. Med. (1986) 163:1433–50.
   PubMed Web of Science ®Google Scholar
• NAWROTH PP, BANK I, HANDLEY D, CASSIMERIS J, CHESS L, STERN D. Tumor necrosis factor/cachectin interacts with endothelial cell receptors to induce release of interleukin 1.1 Exp. Med. (1986) 163:1363–75.
   PubMed Web of Science ®Google Scholar
• DAYER J-M, BEUTLER B, CERAMI A. Cachectin/tumornecrosis factor stimulates collagenase and prosta-glandin E2 production by human synovial cells and dermal fibroblasts. J. Exp. Med. (1985) 162:2163–68.
   Google Scholar
• TRACEY KJ, VLASSARA H, CERAMI A: Cachectin/tumournecrosis factor. Lancet (1989) 1:1126.
   PubMedGoogle Scholar
• SECKINGER P, ZHANG J, HAUPTMANN B et al.: Charac-terization of a tumor necrosis factor a (TNF-a) inhibitor: Evidence of immunological cross-reactivity with the TNF receptor. Proc. Natl. Acad. Sci. USA (1990) 87:5188–5192.
   PubMed Web of Science ®Google Scholar
• BANNER DW, D'ARCY A et al.: Crystal structure of thesoluble human 55 kd TNF receptor-human TNF beta complex: Implications for TNF receptor activation. Cell (1993) 73:341–445.
   Google Scholar
• ENGELMANN H, ADERKA D, RUBINSTEIN M et al.: Atumor necrosis factor binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. J. Biol. Chem. (1989) 264:11974–11980.
   PubMed Web of Science ®Google Scholar
• OLSSON I, LANTZ M, NILSSON E et al.: Isolation and characterization of a tumor necrosis factor binding protein from urine. Eur.J. Haematol (1989) 42:270–275.
   PubMed Web of Science ®Google Scholar
• COPE AP, ADERKA D, DOHERTY M et al.: Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases. Arthritis Rheum. (1992) 35:1160.
   PubMed Web of Science ®Google Scholar
• ROUX-LOMBARD P, PUNZI L, HASLER F et al.: Solubletumor necrosis receptors in human inflammatory synovial fluids. Arthritis Rheum. (1993) 36:485.
   PubMed Web of Science ®Google Scholar
• MORELAND LW, MARGOLIES GR, HECK LW et al.: Recombinant soluble tumor necrosis factor receptor (OW fusion protein: Toxicity and dose finding trial in refractory rheumatoid arthritis. J. Rheumatol. (1996) 23:1849–1855.
   PubMed Web of Science ®Google Scholar
• NAM MH, REDA D, BOUJOUKO S et al.: Recombinanthuman chimeric tumor necrosis factor (TNF) receptor (TNFR:Fc): Safety and pharmacokinetics in humans [abstract]. Clin. Res. (1993) 41:249A.
   Google Scholar
• MORELAND LW, BAUMGARTNER SW, SCHIFF MH et al.:Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. New Engl. J. Med. (1997) 337:141–147.
   PubMed Web of Science ®Google Scholar
• MORELAND LW, SCHIFF MH, BAUMGARTNER SW et al.: Etanercept therapy in rheumatoid arthritis. Ann. Intern. Med. (1999) 130:478–86.
   PubMed Web of Science ®Google Scholar
• WEINBLATT ME, KREMER JM, BANKHURST AD et al.: A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. New Engl. J. Med. (1999) 340:253–9.
   PubMed Web of Science ®Google Scholar
• MORELAND LW, BAUMGARTNER SW, TINDALL E et al: Long term safety and efficacy of TNF receptor (p75) Fc fusion protein (TNFR:Fc, Enbrel'il in DMARD refrac-tory rheumatoid arthritis (RA). Arthritis Rheum. (1998) 41 (Suppl.):S364.
   Google Scholar
• LOVELL DJ, GIANNINI EH, WHITMORE JB et al.: Safety and efficacy of tumor necrosis factor receptor p75 fusion protein (TNFR:Fc, Enbrerl in polyarticular course juvenile rheumatoid arthritis (RA). Arthritis Rheum. (1998) 41 (Suppl.):S470.
   Google Scholar